Evaluation and Management of Cardiovascular Risk Factors in Inflammatory and Acquired Dysimmune Diseases (CARMIN)
NCT ID: NCT02835547
Last Updated: 2016-07-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
600 participants
OBSERVATIONAL
2009-02-28
2015-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The project CARMIN involves the assessment of cardiovascular risk factors, their management, and their influence on cardiovascular prognosis in patients with autoimmune diseases and immunodeficiencies acquired. It is based on the creation and monitoring of a cohort of patients with different types of dysimmune disorders: systemic lupus erythematosus, rheumatoid arthritis, psoriasis, scleroderma, systemic vasculitis ANCA, kidney transplants, and hematopoietic stem cells transplants.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Intracoronary Analysis of Cardiac Allograft Vasculopathy by Means of Optical Coherence Tomography
NCT02254668
Adverse Myocardial and Vascular Side Effects of Immune Checkpoint Inhibitors
NCT04586894
Improving Immunosuppressive Therapy in Heart Transplantation
NCT03932539
Study to Evaluate the Efficacy of Immunosuppression in Myocarditis or Inflammatory Cardiomyopathy.
NCT04654988
Trial on Vascular Inflammation in Atopic Dermatitis
NCT02926807
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Systemic lupus erythematosus
Data collection of risk factors (collected retrospectively - 5 years) and cardiovascular events (collected prospectively - 2 years).
Data collection
Risk factors will be collected retrospectively (5 years) and cardiovascular events prospectively (2 years)
Rheumatoid arthritis
Data collection of risk factors (collected retrospectively - 5 years) and cardiovascular events (collected prospectively - 2 years).
Data collection
Risk factors will be collected retrospectively (5 years) and cardiovascular events prospectively (2 years)
Psoriasis
Data collection of risk factors (collected retrospectively - 5 years) and cardiovascular events (collected prospectively - 2 years).
Data collection
Risk factors will be collected retrospectively (5 years) and cardiovascular events prospectively (2 years)
Scleroderma
Data collection of risk factors (collected retrospectively - 5 years) and cardiovascular events (collected prospectively - 2 years).
Data collection
Risk factors will be collected retrospectively (5 years) and cardiovascular events prospectively (2 years)
Hematopoietic stem cells transplants
Data collection of risk factors (collected retrospectively - 5 years) and cardiovascular events (collected prospectively - 2 years).
Data collection
Risk factors will be collected retrospectively (5 years) and cardiovascular events prospectively (2 years)
Kidney transplants
Data collection of risk factors (collected retrospectively - 5 years) and cardiovascular events (collected prospectively - 2 years).
Data collection
Risk factors will be collected retrospectively (5 years) and cardiovascular events prospectively (2 years)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Data collection
Risk factors will be collected retrospectively (5 years) and cardiovascular events prospectively (2 years)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The diagnosis of the pathology selected for this study based on a clear clinical and biological evaluation supported by criteria specific to each pathology and compatible with international standards.
* Date of diagnosis should not be less than 5 years (+/- 1 year), except for scleroderma patients where it has been extended to 10 years.
* For kidney transplant patients the investigators take into account only patients with a maximum of 2 years of dialysis before graft.
Exclusion Criteria
* HIV seropositive
* Patients with multiple pathologies
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospices Civils de Lyon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D50841
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.